Brief: Cstone Pharmaceuticals Announced The IND Approval Of CS5001 By U.S. Food And Drug Administration
03/01/2022 24:03
Jan 2 (Reuters) - CStone Pharmaceuticals 2616.HK :
* ANNOUNCED THE IND APPROVAL OF CS5001, A POTENTIAL GLOBAL
BEST-IN-CLASS ROR1-TARGETING ADC BY THE U.S. FOOD AND DRUG
ADMINISTRATION
* HAVE ALREADY SUBMITTED CTN APPLICATION IN AUSTRALIA AND
PLAN TO
SUBMIT IND APPLICATION IN CHINA SOON
Source text for Eikon: ID:nPnbT7q2Fa
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026